Project Grant R01HL174452
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$638K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $827,753.90 to Bloodworks, a non-profit organization in Seattle, to conduct research on oxidative cysteine modification by thiol isomerases and its role in vaso-occlusive events in sickle cell disease. The research aims to mechanistically examine how protein disulfide isomerase (PDI) senses the redox environment in sickle cell disease, catalyze electron...
This Project Grant award of $179,280 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Pennsylvania supports research investigating the impact of diet and nutritional stress on neutrophil function and sickle cell disease pathology. The project aims to evaluate how early life nutritional exposures shape neutrophil development and function, and how this in turn modulates the severity of sickle cell disease. By leveraging...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $608,126 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The project aims to (1) define the relationship between common SCD adverse clinical outcomes and single-cell biochemical and mechanical properties, (2) determine the relationship between treatment responses...
This Project Grant award of $465,000.00 from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into the mechanisms by which chronic inflammation disrupts the hemostatic function of platelets and red blood cells in sickle cell disease (SCD). The research aims to elucidate how tumor necrosis factor-alpha (TNFα)-driven inflammation in SCD blocks autophagy and mitophagy in platelets and reticulocytes, leading to the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on characterizing the role of the alternative complement pathway in the pathogenesis of acute chest syndrome (ACS) in sickle cell disease (SCD). The key objectives are to: 1) define the mechanisms by which complement contributes to the development of ACS using novel preclinical models, microfluidics, and in vitro assays; 2) characterize...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to characterize the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease (SCD). The $1,449,454 award to the University of North Carolina at Chapel Hill (UNC-CH) will fund research to: 1) identify disease-specific triggers of FXII activation, 2) characterize FXII effects on neutrophil...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $445,000.00 to The Children's Hospital Of Philadelphia Research Institute to conduct research on the role of neutrophil extracellular traps (NETs) in thromboinflammatory diseases. The key objectives are to: 1) characterize the role of NETs in immune homeostasis, 2) define the mechanism by which platelet factor 4 (PF4) and an Fc-modified antibody enhance NET-mediated...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $202,366 to Emory University to investigate the role of heme-induced complement activation in sickle cell disease (SCD) pregnancy. The primary objectives are to: 1) Characterize the effects of SCD and heme-induced complement activation on pregnancy outcomes in a mouse model of SCD (K99 phase), and 2) Determine if heme and/or complement modulation can improve...